Kramer, Andre, Prinz, Carolin, Fichtner, Falk, Fischer, Anna-Lena, Thieme, Volker, Grundeis, Felicitas, Spagl, Manuel, Seeber, Christian, Piechotta, Vanessa, Metzendorf, Maria-Inti, Golinski, Martin, Moerer, Onnen, Stephani, Caspar, Mikolajewska, Agata, Kluge, Stefan, Stegemann, Miriam, Laudi, Sven and Skoetz, Nicole (2022). Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. (6). HOBOKEN: WILEY. ISSN 1361-6137

Full text not available from this repository.

Abstract

Background With potential antiviral and anti-inflammatory properties, Janus kinase (JAK) inhibitors represent a potential treatment for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They may modulate the exuberant immune response to SARS-CoV-2 infection. Furthermore, a direct antiviral effect has been described. An understanding of the current evidence regarding the efficacy and safety of JAK inhibitors as a treatment for coronavirus disease 2019 (COVID-19) is required. Objectives To assess the effects of systemic JAK inhibitors plus standard of care compared to standard of care alone (plus/minus placebo) on clinical outcomes in individuals (outpatient or in-hospital) with any severity of COVID-19, and to maintain the currency of the evidence using a living systematic review approach. Search methods We searched the Cochrane COVID-19 Study Register (comprising MEDLINE, Embase, ClinicalTrials.gov, World Health Organization (WHO) International Clinical Trials Registry Platform, medRxiv, and Cochrane Central Register of Controlled Trials), Web of Science, WHO COVID-19 Global literature on coronavirus disease, and the US Department of Veterans Affairs Evidence Synthesis Program (VA ESP) Covid-19 Evidence Reviews to identify studies up to February 2022. We monitor newly published randomised controlled trials (RCTs) weekly using the Cochrane COVID-19 Study Register, and have incorporated all new trials from this source until the first week of April 2022. Selection criteria We included RCTs that compared systemic JAK inhibitors plus standard of care to standard of care alone (plus/minus placebo) for the treatment of individuals with COVID-19. We used the WHO definitions of illness severity for COVID-19. Data collection and analysis We assessed risk of bias of primary outcomes using Cochrane's Risk of Bias 2 (RoB 2) tool. We used GRADE to rate the certainty of evidence for the following primary outcomes: all-cause mortality (up to day 28), all-cause mortality (up to day 60), improvement in clinical status: alive and without need for in-hospital medical care (up to day 28), worsening of clinical status: new need for invasive mechanical ventilation or death (up to day 28), adverse events (any grade), serious adverse events, secondary infections. Main results We included six RCTs with 11,145 participants investigating systemic JAK inhibitors plus standard of care compared to standard of care alone (plus/minus placebo). Standard of care followed local protocols and included the application of glucocorticoids (five studies reported their use in a range of 70% to 95% of their participants; one study restricted glucocorticoid use to non-COVID-19 specific indications), antibiotic agents, anticoagulants, and antiviral agents, as well as non-pharmaceutical procedures. At study entry, about 65% of participants required low-flow oxygen, about 23% required high-flow oxygen or non-invasive ventilation, about 8% did not need any respiratory support, and only about 4% were intubated. We also identified 13 ongoing studies, and 9 studies that are completed or terminated and where classification is pending. Individuals with moderate to severe disease Four studies investigated the single agent baricitinib (10,815 participants), one tofacitinib (289 participants), and one ruxolitinib (41 participants). Systemic JAK inhibitors probably decrease all-cause mortality at up to day 28 (95 of 1000 participants in the intervention group versus 131 of 1000 participants in the control group; risk ratio (RR) 0.72, 95% confidence interval (CI) 0.57 to 0.91; 6 studies, 11,145 participants; moderate-certainty evidence), and decrease all-cause mortality at up to day 60 (125 of 1000 participants in the intervention group versus 181 of 1000 participants in the control group; RR 0.69, 95% CI 0.56 to 0.86; 2 studies, 1626 participants; high-certainty evidence). Systemic JAK inhibitors probably make little or no difference in improvement in clinical status (discharged alive or hospitalised, but no longer requiring ongoing medical care) (801 of 1000 participants in the intervention group versus 778 of 1000 participants in the control group; RR 1.03, 95% CI 1.00 to 1.06; 4 studies, 10,802 participants; moderate-certainty evidence). They probably decrease the risk of worsening of clinical status (new need for invasive mechanical ventilation or death at day 28) (154 of 1000 participants in the intervention group versus 172 of 1000 participants in the control group; RR 0.90, 95% CI 0.82 to 0.98; 2 studies, 9417 participants; moderate-certainty evidence). Systemic JAK inhibitors probably make little or no difference in the rate of adverse events (any grade) (427 of 1000 participants in the intervention group versus 441 of 1000 participants in the control group; RR 0.97, 95% CI 0.88 to 1.08; 3 studies, 1885 participants; moderate-certainty evidence), and probably decrease the occurrence of serious adverse events (160 of 1000 participants in the intervention group versus 202 of 1000 participants in the control group; RR 0.79, 95% CI 0.68 to 0.92; 4 studies, 2901 participants; moderate-certainty evidence). JAK inhibitors may make little or no difference to the rate of secondary infection (111 of 1000 participants in the intervention group versus 113 of 1000 participants in the control group; RR 0.98, 95% CI 0.89 to 1.09; 4 studies, 10,041 participants; low-certainty evidence). Subgroup analysis by severity of COVID-19 disease or type of JAK inhibitor did not identify specific subgroups which benefit more or less from systemic JAK inhibitors. Individuals with asymptomatic or mild disease We did not identify any trial for this population. Authors' conclusions In hospitalised individuals with moderate to severe COVID-19, moderate-certainty evidence shows that systemic JAK inhibitors probably decrease all-cause mortality. Baricitinib was the most often evaluated JAK inhibitor. Moderate-certainty evidence suggests that they probably make little or no difference in improvement in clinical status. Moderate-certainty evidence indicates that systemic JAK inhibitors probably decrease the risk of worsening of clinical status and make little or no difference in the rate of adverse events of any grade, whilst they probably decrease the occurrence of serious adverse events. Based on low-certainty evidence, JAK inhibitors may make little or no difference in the rate of secondary infection. Subgroup analysis by severity of COVID-19 or type of agent failed to identify specific subgroups which benefit more or less from systemic JAK inhibitors. Currently, there is no evidence on the efficacy and safety of systemic JAK inhibitors for individuals with asymptomatic or mild disease (non-hospitalised individuals).

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kramer, AndreUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Prinz, CarolinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fichtner, FalkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, Anna-LenaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thieme, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grundeis, FelicitasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spagl, ManuelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seeber, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Piechotta, VanessaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Metzendorf, Maria-IntiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Golinski, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moerer, OnnenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stephani, CasparUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mikolajewska, AgataUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kluge, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stegemann, MiriamUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Laudi, SvenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Skoetz, NicoleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-688826
DOI: 10.1002/14651858.CD015209
Journal or Publication Title: Cochrane Database Syst Rev.
Number: 6
Date: 2022
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1361-6137
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
SYSTEMATIC REVIEWS; METAANALYSES; BARICITINIB; BIAS; MULTICENTERMultiple languages
Medicine, General & InternalMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/68882

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item